Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 1321 to 1330 of 1334 total matches.

Treatment of Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021  (Issue 1635)
of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human ...
Onychomycosis is caused most commonly by Trichophyton rubrum or T. mentagrophytes. About 10% of all persons worldwide and 40% of those ≥60 years old are believed to have the disease. Risk factors include older age, diabetes, poor peripheral circulation, smoking, HIV infection, psoriasis, and immunosuppression. Left untreated, onychomycosis can cause nail plate destruction, ingrown nails, and (particularly in patients with diabetes) secondary infections. Guidelines on treatment of onychomycosis have been published.
Med Lett Drugs Ther. 2021 Oct 18;63(1635):164-8 |  Show IntroductionHide Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
is a peptide hormone with activity at both glucosedependent insulinotropic polypeptide (GIP) and glucagon ...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 |  Show IntroductionHide Introduction

Insulins for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
in more even activity throughout the dosing period and a longer duration of action. In clinical trials ...
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Med Lett Drugs Ther. 2019 May 6;61(1571):65-8 |  Show IntroductionHide Introduction

Treatment of Clostridioides difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
, it has a narrower spectrum of activity, which limits its effect on the gut microbiome,7 and it is associated ...
Clostridioides (formerly Clostridium) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):137-41 |  Show IntroductionHide Introduction

Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017  (Issue 1525)
; 59:39. and generics) to its active form, but whether concurrent use of clopidogrel and omeprazole ...
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-7 |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
the onset of sexual activity, persons ≤26 years old who have already been exposed to HPV or diagnosed ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
or alcohol, or while still active can increase the risk of these behaviors.12 Use of benzodiazepine ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a |  Show IntroductionHide Introduction

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
of any influenza vaccine, pregnant women, persons who are immunocompromised, persons with active ...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50   doi:10.58347/tml.2024.1711a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs That Cause Sexual Dysfunction: An Update

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992  (Issue 876)
function due to anticholinergic and sympatholytic activity or effects on neurotransmitters. Fluoxetine ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Med Lett Drugs Ther. 1992 Aug 7;34(876):73-8 |  Show IntroductionHide Introduction